Modulation of Granulocyte Cells Development by VipAlbumin® Administration in BALB/C Mice with Diabetes Mellitus

Abstract

Diabetes mellitus is a metabolic disease that is caused either by the decrease of insulin secretion from pancreatic β cells or the insensitivity of target cells against insulin. High glucose levels (hyperglycemia condition) can trigger the formation of free radicals, the main cause of diabetes micro and macrovascular complications. The formation of free radicals and AGE (advanced glycation end-products) is assumed to became the key factor in the decline of granulocyte cell production as well as the disruption of these cells functional activity. The purpose of this research was to determine the role of VipAlbumin ® in inhibiting the adverse effects of increased blood glucose levels, which highly influence the production of granulocyte. This study was divided into in vitro and in vivo stage. BALB/C mice were used as experimental animals at in vivo stage and induced to undergo diabetes through 100 mg/kg BW streptozotocin (STZ) injection at the age of 5 days. VipAlbumin® administered orally for 14 days, which began when mice reached the age of 14 weeks. The administration of VipAlbumin® divided into 3 doses i.